Immunotherapy
Immunotherapy added to BRAF/MEK inhibitor improves OS for anaplastic thyroid cancer
Immunotherapy combo shows promising efficacy as first-line treatment for NSCLC
The addition of eftilagimod alpha to pembrolizumab conferred a 40% overall response rate among patients with non-small cell lung cancer unselected for PD-L1, a cohort analysis of the phase 2 TACTI-002 trial showed.
Q&A: ‘Promising’ immunotherapies may treat platinum-resistant ovarian cancer
During their lifetime, one in 70 women will receive a diagnosis of ovarian cancer, which is the second most common gynecologic cancer in the United States, according to Memorial Sloan Kettering Cancer Center.
Fecal transplant may improve response to immunotherapy among patients with melanoma
Fecal microbiota transplant from healthy donors may lower primary resistance to immunotherapy with anti-PD-1 agents among patients with advanced or metastatic melanoma, results of the phase 1 MIMic trial showed.
Sequencing of surgery, immunotherapy impacts outcomes in melanoma
The sequence of surgery and immunotherapy affects outcomes for patients with melanoma, according to a speaker at Chemotherapy Foundation Symposium.
Immunotherapy a ‘significant improvement’ for treatment of multiple myeloma
Despite being behind the curve for adoption of immunotherapy, the field of multiple myeloma has witnessed monumental advances in patient survival with the use of novel agents, according to a speaker at Chemotherapy Foundation Symposium.
Peanut patch reduces reaction severity in toddlers
LOUISVILLE, Ky. — The use of a peanut immunotherapy patch for 12 months appeared to reduce reaction severity while increasing eliciting dose among toddlers, according to results from the phase 3 EPITOPE study.
Immunotherapy skin patch shows efficacy for toddlers with peanut allergy
LOUISVILLE, Ky. — Epicutaneous immunotherapy conferred a significant response after 12 months among children aged 1 to 3 years with peanut allergy, according to results of the phase 3 randomized, double-blind EPITOPE study.
Response-adapted immunotherapy cost-effective, may push melanoma to ‘individualized care’
Response-adapted therapy in melanoma, which involves removal of certain immunotherapeutic agents in a combination, can reduce costs without a decrease in efficacy, according to a study.
VIDEO: Adding immunotherapy for some thyroid cancers shows 'promising preliminary results'
In this video, Jonathan Wadsley, MA, MRCP, FRCR, discussed a symposium on immunotherapy titled "Tumor/immune environment in thyroid cancer: Its exploitation in immunotherapy" given at the American Thyroid Association Annual Meeting.